Close Menu
Rupee WiseRupee Wise
  • Indian Markets
  • Block Deals
  • Commodities
  • Earnings Reports
  • Global Insights
  • Bonds
  • Market Analysis
Recent Posts
  • GIFT Nifty Opens Marginally Down, Signaling Muted Start for Indian Equities
  • NSE Nifty Shows Positive Start: Pre-Open Trade Indicates Upward Momentum
  • GIFT NIFTY Opens Marginally Lower, Signaling Cautious Start for Indian Markets
  • Indian Market Opens with a Slight Dip: Nifty Down 0.18% in Pre-Open Trade
  • Indian Market Pre-Open Shows Positive Start: Nifty Opens Up 0.27%
  • English
  • हिन्दी
Archives
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • July 2024
WhatsApp
WhatsApp
  • English
  • हिन्दी
Rupee WiseRupee Wise
  • Indian Markets
  • Block Deals
  • Commodities
  • Earnings Reports
  • Global Insights
  • Bonds
  • Market Analysis
Rupee WiseRupee Wise
  • English
  • हिन्दी
  • Indian Markets
  • Block Deals
  • Commodities
  • Earnings Reports
  • Global Insights
  • Bonds
  • Market Analysis
Home » Latest News » Markets » Indian Markets

Zydus Lifesciences Secures USFDA Approval for Eluxadoline Tablets

2 months ago Indian Markets 2 Mins Read

Zydus Lifesciences Limited announces it receives final approval from the United States Food and Drug Administration (USFDA) for Eluxadoline tablets, in 75 mg and 100 mg dosages. These tablets are generic versions of Viberzi, originally manufactured by Allergan Pharmaceuticals International Limited. According to industry data, these tablets had annual sales of approximately $243 million in the United States. The approval allows Zydus Life to manufacture and market these tablets in the US, expanding its generic pharmaceutical portfolio. Eluxadoline is used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. The approval signifies a significant milestone for Zydus Life, potentially leading to increased revenue through its presence in the US market.   

Key Insights:

The primary focus of this news is the USFDA’s approval of Zydus Life’s generic Eluxadoline tablets. This approval is a crucial step for Zydus Life as it enables the company to tap into a substantial market for IBS-D medication. The key event is the successful navigation of the USFDA’s rigorous approval process, indicating the quality and efficacy of Zydus Life’s product. Potential impacts include increased market share and revenue for Zydus Life in the US pharmaceutical sector. The approval also reflects positively on Zydus Life’s research and development capabilities and its ability to compete in the highly regulated US market. The annual sales figure of $243 million highlights the market potential for these tablets.  

Investment Implications:

This USFDA approval holds positive implications for Zydus Life’s stock. Investors may witness an increase in the company’s stock value due to the potential revenue growth from the sale of these generic tablets. Considering the substantial annual sales of the branded version, Zydus Life can expect a significant contribution to its earnings. This approval aligns with the broader trend of Indian pharmaceutical companies expanding their presence in the US generic drug market. Investors should monitor Zydus Life’s quarterly earnings reports to assess the actual impact of this approval on the company’s financial performance. Furthermore, investors should also be aware of competition from other generic manufacturers. The health care sector is sensitive to regulatory changes, and the USFDA approval demonstrates the company’s ability to navigate these changes.

Follow on WhatsApp Follow on Google News
Share. WhatsApp Telegram Facebook Twitter Email LinkedIn Copy Link
Avatar of Rajiv Kumar
Rajiv Kumar
  • Website

Rajiv Kumar is a stock broker and financial consultant with a deep understanding of the market. He owns a successful firm where he helps individuals and companies make smart investment decisions. Rajiv provides personalized advice and strategies to help his clients achieve their financial goals. His expertise and commitment to client satisfaction have earned him a strong reputation in the finance industry.

Keep Reading

Indian Markets 3 weeks ago

Aster DM Healthcare Leases Land for New Hospital in Bengaluru

3 Mins Read
Indian Markets 3 weeks ago

Exide Industries’ Q4 FY25 EBITDA Margins Affected by Higher Raw Material Prices

3 Mins Read
Indian Markets 3 weeks ago

Alembic Pharma Anticipates Margin Expansion Driven by R&D Optimization

2 Mins Read
Indian Markets 3 weeks ago

Paytm Reaffirms Margin Targets, Highlights Earnings Potential

3 Mins Read
Indian Markets 3 weeks ago

Welspun Corp Secures Significant Export Order for Coated LSAW Line Pipes and Bends from India

2 Mins Read
Indian Markets 3 weeks ago

Techno Electric Launches Digital Infrastructure Arm with USD 1 Billion Investment Plan

3 Mins Read
Indian Markets 3 weeks ago

Report of Sumitomo Acquiring 51% Stake in YES BANK Incorrect, Say Banking Sources

2 Mins Read
Indian Markets 3 weeks ago

Meghna Infracon Board to Consider Bonus Share Issuance

2 Mins Read
Indian Markets 3 weeks ago

Hyundai Motor India Celebrates 29 Years of Success with 12.7 Million Units Sold

2 Mins Read
Indian Markets 3 weeks ago

Indian Hotels Confident in Double-Digit Growth Fueled by Expansion and Asset Management

2 Mins Read
Indian Markets 3 weeks ago

Sunteck Realty Expresses Confidence in Continued Growth and Acquisition Strategy

2 Mins Read
Indian Markets 3 weeks ago

Coforge Bullish on FY26 Outlook, Expects Margin Expansion

2 Mins Read
Add A Comment
Leave A Reply Cancel Reply

Latest Posts

GIFT Nifty Opens Marginally Down, Signaling Muted Start for Indian Equities

7 hours ago

NSE Nifty Shows Positive Start: Pre-Open Trade Indicates Upward Momentum

1 day ago

GIFT NIFTY Opens Marginally Lower, Signaling Cautious Start for Indian Markets

2 days ago

Indian Market Opens with a Slight Dip: Nifty Down 0.18% in Pre-Open Trade

3 days ago

Indian Market Pre-Open Shows Positive Start: Nifty Opens Up 0.27%

4 days ago

Nifty50 Closes Strong, Up 0.95% at 24,845.15

7 days ago

NSE Opens Lower: Indian Equities Decline in Pre-Open Trade

1 week ago
Tags
Banking Sector Block Trade Brent Crude Construction Crude Oil DII EBITDA Electric Vehicles Energy Sector FII GIFT Nifty Global Economy India Indian Economy Indian Stock Market Inflation Infrastructure Institutional Investment Institutional Investors Investment Investment Strategy Manufacturing Market Sentiment Market Volatility Mergers and Acquisitions NBFC Nifty 50 Nifty50 NSE Oil Prices OPEC+ Order Book Pharmaceutical Industry Pharmaceuticals Pharmaceutical Sector Power Sector Profitability Q2 Results Quarterly Results Real Estate Renewable Energy Revenue Growth Stock Market निवेश शेयर बाजार
© 2025 RupeeWise. Powered by ABLORE.

Type above and press Enter to search. Press Esc to cancel.